HealthDay News — Based on a draft recommendation statement published by the US Preventive Services Task Force (USPSTF), there is a net benefit for preeclampsia screening with blood pressure measurements through pregnancy, which is categorized as a B recommendation.
Noting that the USPSTF previously established that there is adequate evidence on the accuracy of blood pressure measurements for preeclampsia screening, researchers from the USPSTF conducted a systematic review to examine the direct evidence of benefits and harms of preeclampsia screening on health outcomes.
The researchers found that testing for proteinuria with a dipstick test had low diagnostic accuracy for detection of proteinuria in pregnancy. Furthermore, there was inadequate evidence on the effectiveness of risk prediction for identifying women at high preeclampsia risk. The potential harms of screening for and treatment of preeclampsia were considered no greater than small, with few harms anticipated from blood pressure screening measurements.
Continue Reading
The USPSTF concluded with moderate certainty that there was substantial net benefit for preeclampsia screening with blood pressure measurements through pregnancy. These findings form the basis of a draft recommendation statement.
“If a patient has high blood pressure during a visit, she should receive further testing and evaluation,” Task Force member William R. Phillips, MD, MPH, said in a statement. “Multiple elevated blood pressure measurements are needed to diagnose preeclampsia.”
References
“Draft Recommendation Statement: Preeclampsia: Screening – US Preventive Services Task Force”. Uspreventiveservicestaskforce.org. Updated September 2016. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement167/preeclampsia-screening1. Accessed October 18, 2016.
